l 733060 has been researched along with oxidopamine in 1 studies
| Studies (l 733060) | Trials (l 733060) | Recent Studies (post-2010) (l 733060) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
|---|---|---|---|---|---|
| 71 | 0 | 32 | 8,630 | 6 | 2,407 |
| Protein | Taxonomy | l 733060 (IC50) | oxidopamine (IC50) |
|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thornton, E; Vink, R | 1 |
1 other study(ies) available for l 733060 and oxidopamine
| Article | Year |
|---|---|
Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Cells; Dopaminergic Neurons; Inflammation; Male; Motor Activity; Neurokinin-1 Receptor Antagonists; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Substance P; Substantia Nigra; Tryptophan | 2012 |